Terms: = Ovarian cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Treatment
35 results:
1. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
2. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract] [Full Text] [Related]
3. Charge-conversional click polyprodrug nanomedicine for targeted and synergistic cancer therapy.
Wang Y; Cong Y; Cai M; Liang X; Wang L; Zhou D
J Control Release; 2023 Apr; 356():567-579. PubMed ID: 36924894
[TBL] [Abstract] [Full Text] [Related]
4. Glutathione Transferase P1: Potential Therapeutic Target in ovarian cancer.
Simic P; Pljesa I; Nejkovic L; Jerotic D; Coric V; Stulic J; Kokosar N; Popov D; Savic-Radojevic A; Pazin V; Pljesa-Ercegovac M
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422199
[TBL] [Abstract] [Full Text] [Related]
5. [A Case of Isolated Metachronous Splenic Metastasis after Rectal cancer Surgery].
Kuboyama Y; Sumi T; Sahara Y; Fukushima G; Matsumoto M; Matsudo T; Tachibana S; Mimuro H; Ishibashi Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1688-1690. PubMed ID: 35046298
[TBL] [Abstract] [Full Text] [Related]
6. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract] [Full Text] [Related]
7. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Basaran D; Boerner T; Suhner J; Sassine D; Liu Y; Grisham RN; Tew WP; Gardner GJ; Zivanovic O; Sonoda Y; Long Roche K; Chi DS; Abu-Rustum NR; Soff GA; Jewell EL
Gynecol Oncol; 2021 Oct; 163(1):36-40. PubMed ID: 34312001
[TBL] [Abstract] [Full Text] [Related]
8. NIR Laser Responsive Nanoparticles for ovarian cancer Targeted Combination Therapy with Dual-Modal Imaging Guidance.
Zhao J; Zhang L; Qi Y; Liao K; Wang Z; Wen M; Zhou D
Int J Nanomedicine; 2021; 16():4351-4369. PubMed ID: 34234430
[TBL] [Abstract] [Full Text] [Related]
9. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract] [Full Text] [Related]
10. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract] [Full Text] [Related]
11. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract] [Full Text] [Related]
12. The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological treatment Of ovarian cancer Cells.
Xie W; Zhu S; Yang B; Chen C; Chen S; Liu Y; Nie X; Hao L; Wang Z; Sun J; Chang S
Int J Nanomedicine; 2019; 14():9377-9393. PubMed ID: 31819438
[TBL] [Abstract] [Full Text] [Related]
13. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.
Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S
Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954
[TBL] [Abstract] [Full Text] [Related]
14. Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
McCuaig JM; Tone AA; Maganti M; Romagnuolo T; Ricker N; Shuldiner J; Rodin G; Stockley T; Kim RH; Bernardini MQ
Gynecol Oncol; 2019 Apr; 153(1):108-115. PubMed ID: 30638766
[TBL] [Abstract] [Full Text] [Related]
15. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues.
Xu J; Wang X; Xu P; Liu S; Teng F; Liu X; Zhu Q; Hua X; Gong Z; Jia X
Int J Biochem Cell Biol; 2019 Feb; 107():53-61. PubMed ID: 30543932
[TBL] [Abstract] [Full Text] [Related]
16. Dual-mode imaging and therapeutic effects of drug-loaded phase-transition nanoparticles combined with near-infrared laser and low-intensity ultrasound on ovarian cancer.
Chen S; Liu Y; Zhu S; Chen C; Xie W; Xiao L; Zhu Y; Hao L; Wang Z; Sun J; Chang S
Drug Deliv; 2018 Nov; 25(1):1683-1693. PubMed ID: 30343601
[TBL] [Abstract] [Full Text] [Related]
17. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
Devor EJ; Gonzalez-Bosquet J; Warrier A; Reyes HD; Ibik NV; Schickling BM; Newtson A; Goodheart MJ; Leslie KK
Int J Oncol; 2017 May; 50(5):1721-1728. PubMed ID: 28339050
[TBL] [Abstract] [Full Text] [Related]
18. [The Significance and Limitations of Curative Resection for Peritoneal Metastases of Colorectal cancer].
Yokomizo H; Yoshimatsu K; Yano Y; Okayama S; Sakuma A; Satake M; Yamada Y; Matsumoto A; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Kato H; Naritaka Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1446-1448. PubMed ID: 28133018
[TBL] [Abstract] [Full Text] [Related]
19. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract] [Full Text] [Related]
20. The Lipidomic Analyses in Low and Highly Aggressive ovarian cancer Cell Lines.
Zhao Z; Cai Q; Xu Y
Lipids; 2016 Feb; 51(2):179-87. PubMed ID: 26661829
[TBL] [Abstract] [Full Text] [Related]
[Next]
